Abstract
Introduction: type 2 Diabetes Mellitus (DM2), or non-insulin-dependent, is a chronic disease characterized by insulin resistance or reduced insulin levels, which in turn contribute to high glucose levels. This condition, together with the associated chronic inflammation, generates several complications, one of them is an imbalance in the hemostatic system.Objective: to identify laboratory hemostatic tests and their clinical usefulness in patients with type 2 Diabetes Mellitus.Methods: a bibliographic review was carried out in various databases of interest, including articles published in the last 5 years, in addition to those articles published before 2019 that limited relevant information on the topic.Development: original articles that analyzed hemostatic tests in patients with DM2 were reviewed and it was established that the main tests that are altered are TTP, MPV, fibrinogen, PAI-1, VWF and DD, since they have presented consistent results in different research.Conclusions: it is necessary to perform hemostatic tests in patients with DM2, since it has been seen that untreated patients may present thrombotic disorders that, in the long term, can generate cardiovascular alterations
Publisher
Salud, Ciencia y Tecnologia
Reference35 articles.
1. Centers for Disease Control and Prevention. Datos breves sobre la diabetes | Basics | Spanish | Diabetes | CDC [Internet]. 2022 [cited 2024 Mar 16];Available from: https://www.cdc.gov/diabetes/spanish/basics/quick-facts.html
2. Heredia M, Gallegos E, Heredia M, Gallegos E. Riesgo de diabetes mellitus tipo 2 y sus determinantes. Enfermería Global 2022;21(65):179–202.
3. Organización Panamericana de la Salud. Diabetes - OPS/OMS | Organización Panamericana de la Salud [Internet]. 2023 [cited 2024 Mar 16];Available from: https://www.paho.org/es/temas/diabetes
4. Freire W, Luzuriaga M, Belmont P, Mendieta M, Jaramillo K, Romero N, et al. Encuenta Nacional de Salud y Nutrición. Tomo I. 2014.
5. Pérez J, Gallego N, Velarde C, Franco L, Valencia A. Efecto de la hiperglucemia en el síndrome coronario agudo y sus implicaciones en el tratamiento antiagregante plaquetario. Iatreia 2019;32(2):113–25.